GenMont Biotech Inc (TW:3164) — Market Cap & Net Worth
Market Cap & Net Worth: GenMont Biotech Inc (3164)
GenMont Biotech Inc (TW:3164) has a market capitalization of $44.71 Million (NT$1.42 Billion) as of August 3, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #22260 globally and #1374 in its home market, demonstrating a 0.92% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GenMont Biotech Inc's stock price NT$16.50 by its total outstanding shares 86010364 (86.01 Million). See GenMont Biotech Inc capital spending ratio to understand how much of operating cash flow is reinvested back into capital assets.
GenMont Biotech Inc Market Cap History: 2015 to 2026
GenMont Biotech Inc's market capitalization history from 2015 to 2026. Data shows change from $56.06 Million to $44.71 Million (-1.90% CAGR).
GenMont Biotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GenMont Biotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.12x
GenMont Biotech Inc's market cap is 0.12 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.87x
GenMont Biotech Inc's market cap is 0.87 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $54.33 Million | $540.78 Million | -$235.94 Million | 0.10x | N/A |
| 2017 | $53.17 Million | $380.65 Million | $45.60 Million | 0.14x | 1.17x |
| 2018 | $61.72 Million | $406.53 Million | $158.02 Million | 0.15x | 0.39x |
| 2019 | $60.77 Million | $346.24 Million | $57.45 Million | 0.18x | 1.06x |
| 2020 | $56.40 Million | $325.19 Million | $60.88 Million | 0.17x | 0.93x |
| 2021 | $63.10 Million | $427.93 Million | $113.13 Million | 0.15x | 0.56x |
| 2022 | $64.22 Million | $368.55 Million | $56.98 Million | 0.17x | 1.13x |
| 2023 | $66.93 Million | $318.01 Million | $32.99 Million | 0.21x | 2.03x |
| 2024 | $54.74 Million | $385.37 Million | $57.25 Million | 0.14x | 0.96x |
| 2025 | $49.72 Million | $401.23 Million | $57.20 Million | 0.12x | 0.87x |
Competitor Companies of 3164 by Market Capitalization
Companies near GenMont Biotech Inc in the global market cap rankings as of August 3, 2026.
Key companies related to GenMont Biotech Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
GenMont Biotech Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, GenMont Biotech Inc's market cap moved from $56.06 Million to $ 44.71 Million, with a yearly change of -1.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$44.71 Million | -10.08% |
| 2025 | NT$49.72 Million | -9.16% |
| 2024 | NT$54.74 Million | -18.22% |
| 2023 | NT$66.93 Million | +4.22% |
| 2022 | NT$64.22 Million | +1.77% |
| 2021 | NT$63.10 Million | +11.88% |
| 2020 | NT$56.40 Million | -7.19% |
| 2019 | NT$60.77 Million | -1.54% |
| 2018 | NT$61.72 Million | +16.09% |
| 2017 | NT$53.17 Million | -2.13% |
| 2016 | NT$54.33 Million | -3.09% |
| 2015 | NT$56.06 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of GenMont Biotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $44.71 Million USD |
| MoneyControl | $44.71 Million USD |
| MarketWatch | $44.71 Million USD |
| marketcap.company | $44.71 Million USD |
| Reuters | $44.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GenMont Biotech Inc
GenMont Biotech Incorporation engages in the research and development, manufacture, and sale of various probiotic health products in Taiwan, Singapore, Mainland Chinese, and internationally. The company offers OEM and ODM services, including functional probiotic raw materials, capsules, powder, tablets, and liquid products. GenMont Biotech Incorporation was founded in 2000 and is based in Tainan … Read more